Vikram Kansra
Supercon (United States)(US)
Publications by Year
Research Areas
Nausea and vomiting management, Anesthesia and Pain Management, PARP inhibition in cancer therapy, Ion Transport and Channel Regulation, Pharmacological Receptor Mechanisms and Effects
Most-Cited Works
- → A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection(2013)227 cited
- → A Mitogen-activated Protein Kinase Pathway Is Required for μ-Opioid Receptor Desensitization(1998)143 cited
- → Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials(2015)140 cited
- → EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study(2022)121 cited
- → Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut(2023)119 cited
- → Phosphatidylinositol 3-Kinase-dependent Extracellular Calcium Influx Is Essential for CX3CR1-mediated Activation of the Mitogen-activated Protein Kinase Cascade(2001)54 cited
- → Aging, High Salt Intake, and Renal Dopaminergic Activity in Fischer 344 Rats(1999)53 cited
- → Dopamine causes stimulation of protein kinase C in rat renal proximal tubules by activating dopamine D1 receptors(1995)40 cited
- → Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer(2017)37 cited
- → Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients(2017)37 cited